New Friends of Cancer Research on Alignment of methodologies analyzing real-world data
Friends of Cancer Research shared on LinkedIn:
“New Friends of Cancer Research manuscript in JCO Clinical Cancer Informatics demonstrates the feasibility of aligning disparate real-world (rw) data sources to evaluate rw-response to treatment using clinician-documented response in patients with metastatic non-small cell lung cancer (mNSCLC).
Alignment of methodologies analyzing real-world data (RWD) is critical for supporting evidence generation using these data to inform oncology drug development and regulatory decision-making.
These findings are from the latest pilot project in Friends’ Real-World Evidence Portfolio, which establishes methodologies for using RWD to evaluate safety and efficacy of therapies for patients.
The study assessed data provided by 7 project partners each providing data from 200 patients, indicating that clinician-documented response data was the most available source data for response assessment across datasets, with variability in the availability of imaging data. Real-world response assessed using clinician-stated response was relatively consistent across data sources in an aligned patient population.
Authors: Brittany A. McKelvey, Elizabeth Garrett-Mayer, Donna R. Rivera, Amy Alabaster, Hillary S. Andrews, Elizabeth G. Bond, Thomas D. Brown, Amanda Bruno, Lauren Damato, Janet L. Espirito, Laura L. Fernandes, Eric Hansen, Paul Kluetz, Xinran Ma, Andrea McCracken, Pallavi S. Mishra-Kalyani, Yanina Natanzon, Danielle Potter, Nicholas J. Robert, Lawrence Schwartz, Regina Schwind, Connor Sweetnam, Joseph Wagner, Mark D. Stewart and Jeff D. Allen.
This large-scale coordination led by Friends of Cancer Research is developing best practices and alignment for aggregating and analyzing RWD. ”
